手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| 多発性硬化症歩行スケール-12 (MSWS-12)× | Modified Rankin Scale (mRS)× | |
|---|---|---|
| 分野 | 神経学 | 神経学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 2003 | 1988 |
| 提唱者≠ | Jeremy C. Hobart, University of Plymouth | Rankin scale original (Rankin, 1957); modified version by van Swieten et al. |
| 種類≠ | Self-report questionnaire | Clinician-rated ordinal scale |
| 原典≠ | Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36. DOI ↗ | van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607. DOI ↗ |
| 別名≠ | MS Walking Scale-12, MSWS | mRS, Rankin Scale, Modified Rankin |
| 関連≠ | 3 | 4 |
| 概要≠ | The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility. | The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials. |
| ScholarGateデータセット ↗ |
|
|